



Vaccine Manufacturing Facility – Syria

The Opportunity

Vaccination is a cornerstone of public health, yet Syria currently depends entirely on imported vaccines. This project proposes the establishment of a regional vaccine manufacturing facility to produce key pediatric and adult vaccines, aligned with WHO prequalification standards for humanitarian and regional supply.

Market Demand

- Annual domestic need exceeds 15 million vaccine doses
- Global vaccine market projected to reach \$125B+ by 2030
- High dependence on unstable imports and humanitarian aid
- Strong regional demand from Iraq, Yemen, and Lebanon

Investment Snapshot

- Capital Requirement: \$20–30 million
- Capacity: 30M doses/year (modular expansion possible)
- Target Products: DTP, HepB, polio, measles, influenza
- Breakeven: Year 4–5 with WHO approval pathway

Competitive Advantage

- Alignment with regional immunization programs
- Strong donor and government procurement channels
- Local production reduces cost and import risk
- Opportunity to become a MENA vaccine supplier hub

Strategic Impact

- Increases vaccination coverage and saves lives
- Supports global health security and epidemic response
- Creates 400+ skilled jobs in biotech and production